Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1017569 | 0.98 | CYP1A2 (0.35) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL1018384 | 0.98 | CYP1A2 (0.35) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL23015159 | 0.96 | CYP1A2 (0.34) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL1014592 | 0.93 | — | — | |
| SCHEMBL9746942 | 0.88 | CYP1A2 (0.35) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL9585705 | 0.87 | CYP1A2 (0.39) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL19233495 | 0.85 | MAPT (0.37) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL1016502 | 0.83 | — | — | |
| SCHEMBL1016318 | 0.82 | — | — | |
| SCHEMBL1016960 | 0.81 | MAPT (0.37) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0543919-B1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS IN THE MANUFACTURE OF A MEDICAMENT FOR TREATMENT OF CNS DISEASES | SEARLE & CO (US) | 1996-04-10 | — | — | EP | claimed |
| WO-1992003131-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES | G.D. SEARLE & CO. (US) | 1992-03-05 | — | — | WO | claimed |
| US-8247595-B2 | Organic sulfur compound and its use for controlling harmful arthropod | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| EP-2152668-B1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPODS | SUMITOMO CHEMICAL CO (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100160434-A1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2152668-A1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD | Sumitomo Chemical Company, Limited (JP) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008143338-A1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-11-27 | — | — | WO | disclosed |
| EP-0543919-B1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS IN THE MANUFACTURE OF A MEDICAMENT FOR TREATMENT OF CNS DISEASES | SEARLE & CO (US) | 1996-04-10 | — | — | EP | disclosed |
| US-5462965-A | Use of heterocyclic amino-alcohol compounds for treatment of CNS diseases | GD SEARLE & CO. (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0543919-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES. | SEARLE & CO (US) | 1993-06-02 | — | — | EP | disclosed |
| WO-1992003131-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES | G.D. SEARLE & CO. (US) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160434-A1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD | C5, L3MBTL3, C1S | CYP1A2 487/4885CYP2D6 1737/4885MAPT 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.